{
    "nct_id": "NCT03583164",
    "official_title": "Phase IIb Study of F901318 as Treatment of Invasive Fungal Infections Due to Lomentospora Prolificans, Scedosporium Spp., Aspergillus Spp., and Other Resistant Fungi in Patients Lacking Suitable Alternative Treatment Options",
    "inclusion_criteria": "* Male and female aged at least 18 years, or male and female aged 16 years or 17 years and who weigh at least 40 kg whom have given informed consent\n* Ability and willingness to comply with the protocol.\n* Able to take oral medication\n* Females must be non-lactating and at no risk of pregnancy\n* Male with female partners of childbearing potential must either abstain from sexual intercourse or use a highly effective means of contraception\n* Participants with invasive fungal disease\n* Participants who have limited alternative treatment options\nHealthy volunteers allowed\nMust have minimum age of 16 Years",
    "exclusion_criteria": "* Women who are pregnant or breastfeeding.\n* Known history of allergy, hypersensitivity, or any serious reaction to any component of the study drug.\n* Participants with chronic aspergillosis, aspergilloma or allergic bronchopulmonary aspergillosis.\n* Human Immunodeficiency Virus (HIV) infection but not currently receiving antiretroviral therapy.\n* Participants with a medical condition that may jeopardize adherence to the protocol or may cause unacceptable additional risk to the participant\n* Previously enrolled participants or participants enrolled in any clinical trial within the last 30 days\n* Participants receiving treatment limited to supportive care due to predicted short survival time.\n* Prohibited concomitant medications.\n* Any exclusion criteria required by local regulatory authorities.",
    "miscellaneous_criteria": ""
}